Invention Grant
- Patent Title: Antibody-drug-conjugate and its use for the treatment of cancer
-
Application No.: US17454931Application Date: 2021-11-15
-
Publication No.: US11918656B2Publication Date: 2024-03-05
- Inventor: Ian Rilatt , Michel Perez , Marie Lamothe
- Applicant: PIERRE FABRE MEDICAMENT
- Applicant Address: FR Boulogne-Billancourt
- Assignee: PIERRE FABRE MEDICAMENT
- Current Assignee: PIERRE FABRE MEDICAMENT
- Current Assignee Address: FR Boulogne-Billancourt
- Agency: Finnegan, Henderson, Farabow, Garrett & Dunner, L.L.P.
- Priority: EP 305621 2014.04.25
- The original application number of the division: US15306404
- Main IPC: A61K47/68
- IPC: A61K47/68 ; A61P35/00
Abstract:
The present invention relates to an antibody-drug-conjugate. From one aspect, the invention relates to an anti-body-drug-conjugate comprising an antibody capable of binding to a Target, said antibody being conjugated to at least one drug selected from derivatives of dolastatin 10 and auristatins. The invention also comprises method of treatment and the use of said anti-body-drug-conjugate for the treatment of cancer.
Public/Granted literature
- US20220105195A1 ANTIBODY-DRUG-CONJUGATE AND ITS USE FOR THE TREATMENT OF CANCER Public/Granted day:2022-04-07
Information query
IPC分类:
